2025
Decoding Recurrence in Early-Stage and Locoregionally Advanced Non–Small Cell Lung Cancer: Insights From Electronic Health Records and Natural Language Processing
Lee K, Liu Z, Huang Q, Corrigan D, Kalsekar I, Jun T, Stolovitzky G, Oh W, Rajaram R, Wang X. Decoding Recurrence in Early-Stage and Locoregionally Advanced Non–Small Cell Lung Cancer: Insights From Electronic Health Records and Natural Language Processing. JCO Clinical Cancer Informatics 2025, 9: e2400227. PMID: 40249880, PMCID: PMC12011440, DOI: 10.1200/cci-24-00227.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerDistant metastasis-free survivalRecurrence-free survivalLocoregionally advanced non-small cell lung cancerAdvanced non-small cell lung cancerCell lung cancerStage I-IIIA non-small cell lung cancerNatural language processingLung cancerRecurrence-free survival ratesNon-small cell lung cancer recurrenceRisk factorsEarly-stageCox proportional hazards analysisStage IB patientsMetastasis-free survivalKaplan-Meier analysisNatural language processing systemsLikelihood of recurrenceAnalyze risk factorsProportional hazards analysisLocal/regional recurrenceRFS ratesCurative resectionStage IA
2024
Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective
Pashankar F, Murray M, Gell J, MacDonald N, Shamash J, Billmire D, Klosterkemper L, Olson T, Hirsch M, Lockley M, Stoneham S, Frazier A. Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective. EClinicalMedicine 2024, 69: 102453. PMID: 38544795, PMCID: PMC10965411, DOI: 10.1016/j.eclinm.2024.102453.Peer-Reviewed Original ResearchOvarian immature teratomaImmature teratomaElevated serum alpha-fetoproteinSurgery-only approachSerum alpha-fetoproteinOvarian ITStage IAAdjuvant chemotherapyRare neoplasmsOvarian cancerAdult patientsAlpha-fetoproteinLack of published dataPathologic interpretationPatient managementLow-gradeGrade 1Multiple subspecialtiesPatientsTeratomaYoung femalesAdult practiceNational advisory panelPaediatric teamGCT
2022
Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Mase VJ, Dhanasopon AP, Boffa DJ. Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer. JTO Clinical And Research Reports 2022, 3: 100318. PMID: 35540711, PMCID: PMC9079298, DOI: 10.1016/j.jtocrr.2022.100318.Peer-Reviewed Original ResearchPrevalence of brainBrain metastasesSummary stageBrain imagingN classificationIsolated brain metastasesNode-negative NSCLCRoutine brain imagingStage II NSCLCStage IV NSCLCClinical stage INational Cancer DatabaseEarly-stage NSCLCStage IAStage IIIAStage NSCLCStaging evaluationClinical stageLung cancerCancer DatabaseN stageNSCLCPatientsStage IMetastasis
2021
Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data
Yang SC, Wang JD, Wang SY. Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data. Scientific Reports 2021, 11: 12180. PMID: 34108586, PMCID: PMC8190256, DOI: 10.1038/s41598-021-91852-6.Peer-Reviewed Original ResearchConceptsLead-time biasNational Lung Screening TrialStage shiftStage IALife expectancyCancer patientsLung cancerCalendar yearNationwide cancer registryBenefits of screeningLung cancer patientsReal-world studyLung cancer diagnosisMean life expectancyTomography screeningCancer RegistryLE gainsCancer screeningEarly diagnosisScreening TrialGeneral populationSame pathologyYounger agePathologyCancer diagnosisExpanding Criteria for Prognostic Stage IA in Hormone Receptor–Positive Breast Cancer
Kantor O, King TA, Shak S, Russell CA, Giuliano AE, Hortobagyi GN, Burstein HJ, Winer EP, Dey T, Sparano JA, Mittendorf EA. Expanding Criteria for Prognostic Stage IA in Hormone Receptor–Positive Breast Cancer. Journal Of The National Cancer Institute 2021, 113: 1744-1750. PMID: 34010423, PMCID: PMC8634483, DOI: 10.1093/jnci/djab095.Peer-Reviewed Original ResearchConceptsDisease-specific survivalStage IA patientsStage IAIA patientsPrognostic stagingBreast cancerFive-year disease-specific survivalHormone receptor-positive breast cancerHER2-negative breast cancerReceptor-positive breast cancerN0-1 diseaseN0-1 patientsRecurrence Score resultsEnd Results (SEER) dataAmerican Joint CommitteeAJCC staging systemAJCC eighth editionT1-2N1Primary outcomePrognostic significanceStaging systemTNM categoriesT categoryRS resultsN category
2020
Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan
Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLOS ONE 2020, 15: e0240542. PMID: 33052942, PMCID: PMC7556438, DOI: 10.1371/journal.pone.0240542.Peer-Reviewed Original ResearchRisk‐stratifying clinicopathologic criteria for ovarian preservation in premenopausal women with early stage low‐risk endometrial cancer
Khadraoui W, Tierney C, Chung S, Mutlu L, Lu L, Azodi M, Ratner E, Menderes G. Risk‐stratifying clinicopathologic criteria for ovarian preservation in premenopausal women with early stage low‐risk endometrial cancer. International Journal Of Gynecology & Obstetrics 2020, 150: 385-391. PMID: 32506422, DOI: 10.1002/ijgo.13254.Peer-Reviewed Original ResearchConceptsEarly-stage diseaseEndometrioid endometrial cancerEndometrial cancerOvarian preservationPremenopausal womenStage diseaseMetastatic diseaseGrade 1 endometrioid endometrial cancerEarly-stage endometrial cancerLow-risk endometrial cancerEarly-stage endometrioid endometrial cancerStage endometrial cancerStage II diseaseSingle institutional databaseFrozen section specimenQuality of lifeSignificant health benefitsIIA diseaseAdnexal involvementStage IAEndometrial biopsyOvarian involvementRetrospective reviewMyometrial biopsiesClinicopathologic criteria
2019
TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients
Villalba M, Exposito F, Pajares MJ, Sainz C, Redrado M, Remirez A, Wistuba I, Behrens C, Jantus-Lewintre E, Camps C, Montuenga LM, Pio R, Lozano MD, de Andrea C, Calvo A. TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients. Journal Of Clinical Medicine 2019, 8: 2134. PMID: 31817025, PMCID: PMC6947244, DOI: 10.3390/jcm8122134.Peer-Reviewed Original ResearchTMPRSS4 protein expressionNSCLC patientsHigh riskEighth TNM staging systemCell lung cancer patientsEarly-stage NSCLC patientsEighth TNM classificationOverall survival HRRelapse/deathStage IA tumorsProtein expressionIndependent prognostic factorYear of diagnosisTNM staging systemStage NSCLC patientsLung cancer patientsBronchoalveolar lavage samplesCase-control studyNon-invasive biomarkersLiquid biopsy biomarkersIA tumorsStage IAPrognostic factorsRelapse rateTNM classification
2018
P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy
Woodard G, Wang S, Kratz J, Haro G, Gubens M, Blakely C, Jahan T, Jones K, Mann M, Jablons D. P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy. Journal Of Thoracic Oncology 2018, 13: s835. DOI: 10.1016/j.jtho.2018.08.1487.Peer-Reviewed Original Research
2017
Immature Ovarian Teratoma
Faure-Conter C, Pashankar F. Immature Ovarian Teratoma. Journal Of Pediatric Hematology/Oncology 2017, 39: 487-489. PMID: 28859031, DOI: 10.1097/mph.0000000000000950.Peer-Reviewed Original ResearchConceptsOvarian immature teratomaImmature teratomaPure ovarian immature teratomaFIGO stage IARole of chemotherapyImmature ovarian teratomaGrade 1 tumorsStandard of careAdjuvant chemotherapyAdult oncologistsMalignant relapseStage IAPediatric seriesOvarian teratomaPediatric teamAdult womenChemotherapyTumorsTeratomaUrgent needRelapsePatientsSurgeryOncologistsPediatricsAdjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer
Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2017, 19: 58-64. PMID: 28645632, DOI: 10.1016/j.cllc.2017.05.015.Peer-Reviewed Original ResearchConceptsHigh-risk patientsDisease-free survivalLow-risk patientsAdjuvant chemotherapyNational Comprehensive Cancer Network guidelinesCell lung cancer patientsMolecular profilingEarly-stage NSCLCHigh-risk criteriaLog-rank analysisCell lung cancerHigh-risk designationLung cancer patientsKaplan-Meyer estimatesAdjuvant treatmentNonsquamous NSCLCOccult metastasesStage IAStage NSCLCAdjuvant interventionClinicopathologic characteristicsComplete resectionConsecutive patientsDisease recurrenceNCCN criteriaA Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma
Husain ZA, Chen T, Corso CD, Wang Z, Park H, Judson B, Yarbrough W, Deshpande H, Mehra S, Kuo P, Decker RH, Burtness BA. A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma. JAMA Oncology 2017, 3: 358-365. PMID: 27737449, DOI: 10.1001/jamaoncol.2016.4581.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell cancerAJCC/UICC systemStaging systemStage IAStage IBHuman papillomavirusPrognostic abilityUICC systemAJCC/UICC staging systemStage IICurrent American Joint CommitteeOropharyngeal squamous cell carcinomaInternational Cancer Control (UICC) staging systemOropharyngeal cancer NetworkNational Cancer DatabasePrimary radiation therapyOverall survival rateAmerican Joint CommitteeCancer/UnionEdition staging systemKaplan-Meier methodSquamous cell cancerNovel staging systemSquamous cell carcinomaLog-rank test
2014
Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer
Woodard GA, Gubens MA, Jahan TM, Jones KD, Kukreja J, Theodore PR, Cardozo S, Jew G, Clary-Macy C, Jablons DM, Mann MJ. Prognostic Molecular Assay Might Improve Identification of Patients At Risk for Recurrence in Early-Stage Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2014, 15: 426-432. PMID: 25258195, DOI: 10.1016/j.cllc.2014.07.004.Peer-Reviewed Original ResearchConceptsHigh-risk patientsLow-risk patientsStage IBNCCN criteriaNCCN guidelinesRisk stratificationHigh-risk clinicopathologic featuresEarly-stage NSCLC patientsAdjuvant chemotherapy recommendationsMonths of patientsMolecular risk stratificationCell lung cancerIdentification of patientsSmall cohort studiesMolecular risk assessmentBlinded chart reviewMolecular assaysAdjuvant chemotherapyChemotherapy recommendationsNonsquamous NSCLCStage IAChart reviewCohort studyNSCLC patientsRecurrence outcomes
2005
Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy
Kelly MG, O'Malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, Azodi M, Schwartz PE. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecologic Oncology 2005, 98: 353-359. PMID: 16005947, DOI: 10.1016/j.ygyno.2005.06.012.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleChemotherapy, AdjuvantCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousDilatation and CurettageDisease-Free SurvivalFemaleHumansHysterectomyNeoplasm StagingOrganoplatinum CompoundsRetrospective StudiesUterine NeoplasmsConceptsUterine papillary serous carcinomaPlatinum-based chemotherapyResidual uterine diseaseStage IA patientsVaginal cuff radiationAdjuvant platinum-based chemotherapySurgical stage IPapillary serous carcinomaIA patientsUterine diseaseStage IHysterectomy specimenOverall survivalSerous carcinomaConcomitant platinum-based chemotherapyImproved disease-free survivalComplete surgical stagingStage IB patientsStage IC patientsDisease-free survivalHigh recurrence rateVaginal radiationAdjuvant therapyStage IASurgical stagingRacial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): A major prognostic indicator in uterine serous papillary cancer
Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): A major prognostic indicator in uterine serous papillary cancer. American Journal Of Obstetrics And Gynecology 2005, 192: 813-818. PMID: 15746676, DOI: 10.1016/j.ajog.2004.10.605.Peer-Reviewed Original ResearchConceptsHER2/neu expressionEndometrial cancerNeu expressionProportional hazards modelWhite patientsBlack patientsPoor outcomeHigh HER2/neu expressionUterine serous papillary cancerCox proportional hazards modelHER2/neu overexpressionEndometrial cancer survivalMultivariate Cox regressionMajor prognostic indicatorHER2/neu oncogeneRacial differencesNovel treatment strategiesHER2/neuType II receptorStage IAAggressive variantMultivariable analysisUnivariable analysisCorpus uteriCox regression
2004
Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation
Kelly MG, O'Malley D, Hui P, McAlpine J, Dziura J, Rutherford TJ, Azodi M, Chambers SK, Schwartz PE. Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecologic Oncology 2004, 95: 469-473. PMID: 15581948, DOI: 10.1016/j.ygyno.2004.08.030.Peer-Reviewed Original ResearchConceptsUterine papillary serous carcinomaStage IA patientsResidual uterine diseaseAdvanced stage uterine papillary serous carcinomaIA patientsUterine diseaseSerous cancerUterine papillary serous cancerComplete surgical stagingObstetrics stage IAPapillary serous cancerDifferent therapeutic optionsPapillary serous carcinomaPlatinum-based chemoradiationMore effective treatmentsLocoregional diseaseHysterectomy specimenStage IAStage IIIAStage IIICSurgical stagingExtrauterine metastasesSerous carcinomaTherapeutic optionsFallopian tube046 Racial Differences in Overexpression of Epidermal Growth Factor Type II Receptor (HER2/NEU): A Major Prognostic Indicator and Novel Therapeutic Target in Uterine Serous Papillary Cancer
Santin A, Bellone S, Siegel E, Kay H, Roman J, Burnett A, Pecorelli S. 046 Racial Differences in Overexpression of Epidermal Growth Factor Type II Receptor (HER2/NEU): A Major Prognostic Indicator and Novel Therapeutic Target in Uterine Serous Papillary Cancer. International Journal Of Gynecological Cancer 2004, 14: 14. DOI: 10.1136/ijgc-00009577-200409001-00046.Peer-Reviewed Original ResearchAssociated with poor outcomesHER2/neu expressionAA patientsPoor outcomeFrequency of HER2/neu overexpressionSerous papillary endometrial cancerUterine serous papillary cancerImplementation of novel treatment strategiesClinical management of patientsOverexpression of HER2/neuMultivariate Cox regressionEndometrial cancer survivalManagement of patientsNovel treatment strategiesType II receptorStage IAHER2/neu overexpressionNovel therapeutic targetsPapillary cancerCaucasian patientsCorpus uteriEndometrial cancerShorter survivalPrognostic indicatorHER2/neu oncogeneSelective incorporation of total laparoscopic hysterectomy for adnexal pathology and body mass index
O'Hanlan KA, Huang GS, Lopez L, Garnier AC. Selective incorporation of total laparoscopic hysterectomy for adnexal pathology and body mass index. Gynecologic Oncology 2004, 93: 137-143. PMID: 15047227, DOI: 10.1016/j.ygyno.2003.12.020.Peer-Reviewed Original ResearchConceptsTotal laparoscopic hysterectomyBody mass indexAdnexal pathologyUrological injuriesLaparoscopic hysterectomyBMI groupsMass indexOvarian carcinomaExact testRecurrent breast cancerMean surgery durationMean complication rateFisher's exact testObstructive adhesionsEarly complicationsHospital stayStage IAChart abstractionComplication rateNodal yieldBlood lossOvarian pathologyMucinous cystadenomaPelvic massMean age
2001
Emerging therapies in non-small-cell lung cancer
Khuri FR, Herbst RS, Fossella FV. Emerging therapies in non-small-cell lung cancer. Annals Of Oncology 2001, 12: 739-744. PMID: 11484947, DOI: 10.1023/a:1011197500223.Peer-Reviewed Original ResearchConceptsCell lung cancerLung cancerCancer-related deathFive-year survival rateRole of chemotherapyMultiple randomized trialsAdvanced diseaseStage IADevastating causeMetastatic diseaseModality therapyOnly patientsRandomized trialsStage IVSurvival rateNew casesCancerChemotherapyTherapyDiseaseDeathPatientsYear 2000Trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply